Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
13 February 2025

MidCap Events Frankfurt 2025

Steigenberger Icon Hotel

Frankfurt

Germany

4 February 2025

Invest Securities BioMed Forum 2025

Salons Hoche

Paris

France

13-15 January 2025

14th Annual LifeSci Advisors Corporate Access Event

Beacon Grand Hotel in San Francisco

CA

United States

12 January 2025

8th Sachs Annual Neuroscience Innovation Forum

Marines’ Memorial Club in San Francisco

CA

United States

9 January 2025

ORYZON to provide corporate progress updates at several events in January-February

11 December 2024

Video: Edison Group - executive interview with our CEO

2 December 2024

ORYZON continues to strengthen its patent portfolio for vafidemstat

12 November 2024

Video: Watch an interview with our CEO at BIO-Europe

31 October 2024

ORYZON receives Notice of allowance for patent on novel technology for measuring LSD1 target engagement

24 October 2024

ORYZON reports financial results and corporate update for quarter ended September 30, 2024

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel